Investors are pouring money into medical outpatient buildings just as pharma races to decentralize clinical research. The overlap is starting to look less like coincidence. When you look at the latest U.S. office numbers, it might appear that medical and pharmaceutical companies are retreating from real estate. Central business district towers are struggling with high…
Precision medicine made trials smarter. It also made recruitment harder.
In statistics and machine learning, there’s a tradeoff between precision and recall: tune a system to be more selective and you inevitably miss more true positives. Cancer clinical trials have stumbled into a similar trap. As oncology has shifted from tumor-type-centered studies to gene-directed approaches, eligibility criteria have grown exquisitely precise. Instead of enrolling patients…